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Introduction
Blau’s syndrome is an autosomal-dominant, autoinflam-
matory disease characterized by a non caseous granuloma-
tous inflammation,presenting with arthritis, dermatitis and
uveitis, caused by mutations of the CARD15/NOD2.
Patients are treated with high doses of oral corticosteroids,
and if the therapeutic response is unsatisfactory,additional
treatment with immunosuppressive agents is the best
choice,such as: Methotrexate,Cyclosporine,Anti-TNF and
Canakinumab (Anti-IL1).
Objectives
Describe a case of Blau syndrome with early onset atypi-
cal manifestations and therapeutic response.
Methods
Case Report
A 2 year old boy was referred to a brazilian Pediatric
Rheumatology center, in march/2009, with daily persistent
high fever, diffuse and firm erythematous rash and polyar-
thritis since age of 3 months old. Laboratory tests showed:
leukocytosis, anaemia and persistent elevation of platelets
count; Immunoglobulins, complements; Zinc,Calcium,
Phosphorus, PTH, 25-hidroxivitamin D e Urine analysis:
normal. Cytomegalovirus, Epstein Barr, toxoplamosis, Par-
vovirus B19, HIV, herpes, Auto-antibodies (FAN, DNA,
SSa, SSb, RNP, Sm, ANCA-p, ANCA-c, anticardiolipine e
lupus anticoagulant): negative. VHS e PCR: elevated; PPD:
nonreactive. Audiometry /Impedanciometry: normal.
Wrist X-Ray: nodular images in 2nd and 5th right meta-
carpals. Skin and synovial biopsy: granulomatous altera-
tions. His mother presented similar history, diagnosed
“systemic JIA” at age of 6, currently presenting articular
deformities and visual loss. Indomethacin, cyclosporine,
methotrexate, colchicine, etanercept and adalimumabe,
were used but the patient remained with fever, rash and
worsening of articular symptoms; ophtalmopathy in left
eye and left ventricular dysfunction. However, there were
no signs of neurological involvement. Canakinumab (Anti
IL1) was started with improvement of all the symptoms.
The genetic test detected genetic mutation in NOD2.
Results
Systemic JIA was initially considered. However, there were
no significant improvement after treatment with predni-
sone, cyclosporine, NSAIDs and Methotrexate. Consider-
ing the very early onset, CINCA syndrome, caused by
mutation of gene CIAS1, was also an important hypoth-
esis. The manifestations of high fever and urticarial rash
starting in first weeks of life; asseptic meningitis leading to
sensorineural hearing and vision loss with persistent eleva-
tion of acute phase reactants, leukocytosis and chronic
anaemia. In spite of the clinical resemblance, cutaneous
granulomatosis and the lack of neurological symptoms
rule out this diagnosis.Finally with the noncaseating gran-
ulomatosus skin biopsy, we considered Blau’s syndrome. It
usually manifests before the first decade of life, with small
and big joint symmetric arthritis, variable erythematous
rash (maculopapular or icthyosiform) and uveitis. The
early onset, the skin rash and the unsatisfactory response
to the initial treatment brought us some doubts. But the
gene mutation in NOD2/CARD15 was conclusive. Blau’s
syndrome can be treated initially with NSAIDs and sys-
temic corticosteroids, however, in cases with ineffective
therapeutic response Anti-TNF and Anti-IL1 can be very
beneficial, especially in patients presenting non responsive
uveitis.
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Conclusion
The atypical manifestation of this case shows the variable
clinical spectrum of monogenic autoinflammatory
syndromes and their resemblances, which makes the early
diagnosis and treatment very challenging.
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